In a nutshell This study compared the effectiveness of TAS-102 (Lonsurf; trifluridine-tipiracil) versus regorafenib (Stivarga) for the treatment of patients with metastatic colorectal cancer (mCRC). The data showed that TAS-102 had better oncologic outcomes than regorafenib in these patients. Some background Colorectal cancer (CRC) is one of the...Read More
Current disease status-Recurrent cancer Posts on Medivizor
Using focal thermo-ablative therapy for treating oligo-recurrent prostate cancer after radiotherapy.
In a nutshell This study assessed patient responses to focal thermo-ablative therapy (FTA) for oligo-recurrent prostate cancer (PCa) after pelvic radiotherapy. The data suggested that FTA therapy is a good option in these patients. Some background Oligometastatic PCa means that cancer has spread to only a few places (up to 5 metastases). It...Read More
Is surgery of metastases effective after failure of modern whole-body treatments in patients with advanced melanoma?
In a nutshell This study looked at the use of surgery for spread disease (metastases) in patients with advanced melanoma when other whole-body treatments had failed. It found that surgical removal of metastases improved the outcomes of these patients. Some background Advanced melanoma can spread to many places in the body. It is usually...Read More
In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including breast cancer, that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment....Read More
In a nutshell This article looked at the effectiveness and safety of anlotinib (AL3818) for non-responsive advanced non-small cell lung cancer (NSCLC). The authors found that anlotinib was an effective third-line or later line therapy for patients with unresponsive advanced NSCLC. Some background NSCLC accounts for 85% of lung cancers found...Read More
In a nutshell This trial is aiming to examine the safety and effectiveness of an experimental treatment called BPX-063, a CAR-T cell treatment, in patients with advanced HER-2 positive breast cancer. The main outcomes to be measured are the maximum tolerated dose of BPX-603 and the antitumor activity. This trial is being carried out across the...Read More
Evaluating belotecan as an alternative treatment for topotecan for sensitive-relapsed small-cell lung cancer.
In a nutshell This study looked at the effectiveness and safety of belotecan (Bel; Camtobell) and topotecan (Top; Hycamtin) as therapy for sensitive relapsed small-cell lung cancer (SCLC). The authors found that Bel could be used as an alternative to Top for sensitive-relapsed SCLC. Some background SCLC...Read More
In a nutshell This trial is looking at the effectiveness of Quad Shot (QS) radiation therapy (RT) to relieve symptoms in patients with advanced non-small-cell lung cancer (NSCLC). The main outcome that is to be measured is the occurrence of side effects over the course of 3-months. This trial is being carried out in New Jersey and New York,...Read More
In a nutshell This study evaluated longer-term survival rates and the safety of olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC). It found that treatment with olaparib led to significantly longer survival, especially in men with gene alterations. Some background CRPC is an especially aggressive...Read More
Osimertinib in EGFR-positive non-small cell lung cancer spread to the brain or the layers surrounding the brain.
In a nutshell This trial was carried out to examine the effectiveness of osimertinib (Tagrisso) in non-small cell lung cancer (NSCLC) that has spread to the brain of the layers of the brain (meninges). The authors concluded that osimertinib showed improved survival and had a good response rate in these patients. Some...Read More
In a nutshell The study compared the quality of life (QoL) of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (Jevtana) compared to abiraterone (Zytiga) or enzalutamide (Xtandi). The authors found that cabazitaxel did not reduce QoL in such patients. Some background Patients with mCRPC...Read More
Comparing regorafenib plus chemotherapy to other biological drugs for the second-line treatment of metastatic colorectal cancer
In a nutshell This analysis was carried out to look at including regorafenib (Stivarga) in second-line therapy for patients with metastatic colorectal cancer (mCRC). The authors found that regorafenib in combination with chemotherapy might be an alternative to standard second-line treatment options for these patients. Some...Read More